Literature DB >> 15840999

Clinical variables related to propofol effect-site concentrations at recovery of consciousness after neurosurgical procedures.

Catarina S Nunes1, David A Ferreira, Luís Antunes, Pedro Amorim.   

Abstract

Target controlled infusion (TCI) systems and computer data acquisition software are increasingly used in anesthesia. It was hypothesized that the use of such systems might allow retrieval of information useful to anticipate the effect-site concentrations of propofol at which patients would recover from anesthesia. The goal of the study was to identify variables related to propofol effect-site concentrations at recovery of consciousness (ROC). Sixteen patients with a Glasgow of 15, ASA 1 or 2, subjected to neurosurgical procedures, received TIVA with TCI propofol and remifentanil. Data were collected every 5 seconds from Datex AS3 and Aspect A200XP (BIS). Effect-site TCI was used for propofol (initial effect target 5.0 microg/ml) and for remifentanil (initial plasma target 2.5 ng/ml). All clinical events were noted. Variables possibly related to propofol effect-site concentration at ROC were selected. Data are expressed as mean +/- SD. Effect-site propofol concentration at ROC was 1.3 +/- 0.5 microg/ml. A positive correlation was found between propofol effect-site concentration at ROC and: age (49.3 +/- 17 years) (P = 0.003); mean remifentanil dose during surgery (0.11 +/- 0.05 microg/kg/min) (P = 0.003); mean propofol dose during surgery (0.12 +/- 0.03 mg/kg/min) (P = 0.046); and remifentanil effect-site concentration at ROC (2.85 +/- 2.06 ng/ml) (P = 0.002). Propofol effect-site concentrations were not correlated with: weight, height, LBM, duration of anesthesia, minimum BIS at induction (30.4 +/- 6.8), time till minimum BIS (4.7 +/- 2.2 min), mean and median BIS during surgery (38.2 +/- 4.5 and 37.8 +/- 5.3). BIS-related variables were not useful as ROC predictors. Only drug variables and age correlated with propofol effect-site concentrations at ROC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15840999     DOI: 10.1097/01.ana.0000163198.02742.9d

Source DB:  PubMed          Journal:  J Neurosurg Anesthesiol        ISSN: 0898-4921            Impact factor:   3.956


  6 in total

1.  A pharmacodynamic analysis of factors affecting recovery from anesthesia with propofol-remifentanil target controlled infusion.

Authors:  Bon-Nyeo Koo; Jeong-Rim Lee; Gyu-Jeong Noh; Jae-Hoon Lee; Young-Ran Kang; Dong-Woo Han
Journal:  Acta Pharmacol Sin       Date:  2012-07-30       Impact factor: 6.150

2.  The influence of initial target effect-site concentrations of propofol on the similarity of effect-sites concentrations at loss and return of consciousness in elderly female patients with the Diprifusor system.

Authors:  Satoshi Shibuta; Seitetsu Kanemura; Osamu Uchida; Takashi Mashimo
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2012-04

3.  Confounding factors to predict the awakening effect-site concentration of propofol in target-controlled infusion based on propofol and fentanyl anesthesia.

Authors:  Shun-Ming Chan; Meei-Shyuan Lee; Chueng-He Lu; Chen-Hwan Cherng; Yuan-Shiou Huang; Chun-Chang Yeh; Chan-Yang Kuo; Zhi-Fu Wu
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

4.  Factors affecting recovery from anaesthesia with propofol-remifentanil target-controlled infusion in laparoscopic surgery.

Authors:  Shao-Hua Liu; Ming Tian
Journal:  J Int Med Res       Date:  2017-05-23       Impact factor: 1.671

5.  Effect site concentration of propofol at induction and recovery of anaesthesia - A correlative dose-response study.

Authors:  Vasanth Sukumar; Arathi Radhakrishnan; Venkatesh H Keshavan
Journal:  Indian J Anaesth       Date:  2018-04

6.  Analysis of anesthesia-controlled operating room time after propofol-based total intravenous anesthesia compared with desflurane anesthesia in functional endoscopic sinus surgery.

Authors:  Tien-Chien Liu; Hou-Chuan Lai; Chueng-He Lu; Yuan-Shiou Huang; Nan-Kai Hung; Chen-Hwan Cherng; Zhi-Fu Wu
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.